Omaveloxolone (RTA408) is a potent Nrf2 transcription factor activator by targeting KEAP1 to prevent Nrf2 ubiquitination and degradation. It exhibits potent antioxidative and anti-inflammatory activities. Omaveloxolone treatment significantly improves mi
